CTT Pharma Submits Proposal for NIH Grant
CTT Pharmaceuticals Holdings (OTC:CTTH) has submitted a grant application to the National Institutes of Health (NIH) to support further research and commercialization of their dissolvable nicotine strips. This submission complements an existing grant with Johns Hopkins University for clinical trials.
The initiative follows CEO Ryan Khouri's presentation at the FDA/NIH hearing for Advancing Smoking Cessation Technology. While the partnership with Johns Hopkins University remains a primary focus, CTT is pursuing additional NIH funding to advance their smoking cessation technology aimed at reducing risks of heart disease, stroke, and various cancers.
A decision on the NIH grant is expected in April 2025.
CTT Pharmaceuticals Holdings (OTC:CTTH) ha presentato una richiesta di finanziamento agli Istituti Nazionali della Salute (NIH) per supportare ulteriori ricerche e la commercializzazione delle loro strisce di nicotina dissolvibili. Questa presentazione integra un finanziamento già esistente con la Johns Hopkins University per prove cliniche.
L'iniziativa segue la presentazione del CEO Ryan Khouri all'udienza FDA/NIH per l'Avanzamento della Tecnologia per la Cessazione del Fumo. Sebbene la partnership con la Johns Hopkins University rimanga un obiettivo primario, CTT sta cercando ulteriori fondi NIH per promuovere la loro tecnologia per la cessazione del fumo mirata a ridurre i rischi di malattie cardiache, ictus e vari tipi di cancro.
Una decisione sul finanziamento NIH è attesa per aprile 2025.
CTT Pharmaceuticals Holdings (OTC:CTTH) ha presentado una solicitud de subvención a los Institutos Nacionales de Salud (NIH) para apoyar la investigación y comercialización de sus tiras de nicotina disolubles. Esta presentación complementa una subvención existente con la Universidad Johns Hopkins para ensayos clínicos.
La iniciativa sigue a la presentación del CEO Ryan Khouri en la audiencia de la FDA/NIH para el Avance de la Tecnología para la Cessación de Fumar. Si bien la asociación con la Universidad Johns Hopkins sigue siendo un enfoque principal, CTT está buscando financiación adicional del NIH para avanzar en su tecnología de cesación del tabaquismo, destinada a reducir los riesgos de enfermedades cardíacas, accidentes cerebrovasculares y diversos tipos de cáncer.
Se espera una decisión sobre la subvención del NIH en abril de 2025.
CTT Pharmaceuticals Holdings (OTC:CTTH)이 국립 보건원 (NIH)에 용해성 니코틴 스트립의 추가 연구 및 상용화를 지원하기 위한 보조금 신청서를 제출했습니다. 이 제출은 존스 홉킨스 대학교와의 임상 시험에 대한 기존 보조금을 보완합니다.
이 이니셔티브는 FDA/NIH의 흡연 중단 기술 진전 청문회에서 CEO 라이언 카우리의 발표를 따릅니다. 존스 홉킨스 대학교와의 파트너십이 주요 초점으로 남아 있지만, CTT는 심장병, 뇌졸중, 다양한 암의 위험을 줄이는 것을 목표로 하는 흡연 중단 기술을 발전시키기 위해 추가 NIH 자금을 추구하고 있습니다.
NIH 보조금에 대한 결정은 2025년 4월에 있을 것으로 예상됩니다.
CTT Pharmaceuticals Holdings (OTC:CTTH) a soumis une demande de subvention aux Instituts Nationaux de la Santé (NIH) pour soutenir des recherches supplémentaires et la commercialisation de leurs bandes de nicotine dissolubles. Cette soumission vient compléter une subvention existante avec l'Université Johns Hopkins pour des essais cliniques.
L'initiative fait suite à la présentation du PDG Ryan Khouri lors de l'audition FDA/NIH pour l'Avancement de la Technologie de Cessation du Tabac. Bien que le partenariat avec l'Université Johns Hopkins reste un objectif principal, CTT recherche un financement NIH supplémentaire pour faire avancer sa technologie de cessation tabagique visant à réduire les risques de maladies cardiaques, d'accidents vasculaires cérébraux et de divers cancers.
Une décision concernant la subvention NIH est attendue en avril 2025.
CTT Pharmaceuticals Holdings (OTC:CTTH) hat einen Antrag auf Zuschuss bei den National Institutes of Health (NIH) eingereicht, um weitere Forschungen und die Kommerzialisierung ihrer löslichen Nikotinstreifen zu unterstützen. Diese Einreichung ergänzt einen bestehenden Zuschuss mit der Johns Hopkins Universität für klinische Studien.
Die Initiative folgt der Präsentation von CEO Ryan Khouri bei der FDA/NIH-Anhörung zur Förderung der Technologien zur Rauchentwöhnung. Während die Partnerschaft mit der Johns Hopkins Universität im Mittelpunkt steht, strebt CTT zusätzliche NIH-Mittel an, um ihre Technologie zur Rauchentwöhnung voranzutreiben, die darauf abzielt, die Risiken von Herzkrankheiten, Schlaganfall und verschiedenen Krebsarten zu reduzieren.
Eine Entscheidung über den NIH-Zuschuss wird für April 2025 erwartet.
- Partnership with Johns Hopkins University for clinical trials
- Potential additional funding through NIH grant
- Development of smoking cessation product with clear medical applications
- Grant approval uncertain
- Commercialization timeline dependent on external funding approval
TAMPA, FL / ACCESS Newswire / January 30, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC:CTTH) has submitted a grant to the National Institutes of Health (NIH) that will aid in further research and commercialization. This grant is being submitted in addition to the Johns Hopkins University grant for clinical trials and this opportunity was suggested to CTT as a grant that would allow for further research and testing.
The CEO of CTT Pharma Ryan Khouri stated, "Approval of this grant will allow for further research that ultimately would lead to commercialization of our dissolvable nicotine strips". This grant opportunity was brought to the attention of Mr. Khouri after he attended and presented at the FDA/NIH hearing for Advancing Smoking Cessation Technology. Mr. Khouri stated that CTT Pharma's partnership with Johns Hopkins University is a main priority to fund and develop CTT's technology as a smoking cessation product, however, additional funding and relationships that can be established with the NIH to help achieve that goal are being pursued. Mr. Khouri looks forward to working with the NIH and FDA in the future and believes CTT can develop products that effectively increase smoking cessation with the resultant reduction of the risk of heart disease, stroke, and various cancers. CTT anticipates a decision made by the NIH in April 2025 and will inform shareholders accordingly.
About CTT Pharmaceuticals Holdings, Inc.
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
When will NIH decide on CTT Pharmaceuticals' (CTTH) grant application?
What is the purpose of CTT Pharmaceuticals' (CTTH) NIH grant application?
What partnerships does CTT Pharmaceuticals (CTTH) have for their smoking cessation product?
What health benefits does CTT Pharmaceuticals (CTTH) aim to achieve with their smoking cessation product?
